胚系DNA错配修复缺陷(mismatch repair damage,dMMR)与结直肠癌(colorectal cancer, CRC)的发生和高肿瘤突变负荷(high tumor mutation burden, TMB-H)相关,有MMR基因突变的CRC患者对免疫检查点抑制剂(immune checkpoint inhibitor, ICI)可能产生更好的响应。 近日,北京大学肿瘤医院消化肿瘤内科彭智副教授与燃石医学合作,...
Background: High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for tumor mutations to generate immunogenic neoantigens. Despite recent pan-cancer approval of ICB treatment for any TMB-H ...
When it comes to patients with lung cancer, tumor mutation burden (TMB) may be the answer, according to recent research presented at the 2019 ASCO Annual Meeting. The Inflammation-Depression Connection Clinicians measured patients’ TMB to determine if they are likely to respond to immunotherapy ...
University of Texas M. D. Anderson Cancer Center Credit: CC0 Public Domain A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses to immune checkpoint inhibitors in a subset of cancer types, according to a...
tumor mutation burdentumor-infiltrating lymphocytesImmune checkpoint inhibitors have been used to treat cancer patients. Non-small cell lung cancer (NSCLC) patients with a high expression level of programmed cell death ligand-1 (PD-L1) could benefit from immune checkpoint inhibitor monotherapy. However...
alterations in DNA damage response and repair (DDR) genes can lead to genetic instability, often accompanied by a high tumor mutation burden (TMB). Howev... JW Kim,HJ Lee,Lee, Ji YoonPark, Sook RyunKim, Yu JungHwang, In GyuKyun Bae, WooByun, Jae HoKim, Jung SunKang, Eun JooLee, ...
MSI-H combined with PD-L1 CPS ≥ 5 (A–C). MSI-H, microsatellite instability-high; MSS, microsatellite stability; Mut, mutation; NDB, no durable benefit; OS, overall survival; PFS, progression-free survival; PD-L1, programmed death ligand 1; TMB, tumor mutation burden; WT, wild ...
MSI-H combined with PD-L1 CPS ≥ 5 (A–C). MSI-H, microsatellite instability-high; MSS, microsatellite stability; Mut, mutation; NDB, no durable benefit; OS, overall survival; PFS, progression-free survival; PD-L1, programmed death ligand 1; TMB, tumor mutation burden; WT, wild ...
(CRC) samples and associations between NEB somatic mutation and CRC patients' tumor mutation burden (TMB) and prognosis by using TCGA-COAD project mutation dataset.Results: Mutational signatures detected from CRC samples indicated pivotal roles of defective DNA damage repair process and polymerase ...
Tumor neoantigen recognition is likely a major factor in the success of clinical immunotherapies1,2,3,4,5and patients with high tumor mutational burden (TMB)6and significant number of neoantigens benefit more from immune checkpoint blockade as well as adoptive cell therapy (ACT) using natural tumo...